Доказательная фармакотерапия синдрома дефицита внимания и гиперактивности

Список литературы

1. 1. Pliszka, S. R. Is There Long-Term Benefit from Stimulant Treatment for ADHD? American Journal of Psychiatry. -2019.-Vol.176(9). – p.685–686
2. 2. Lenzi F. et al. Pharmacotherapy of emotional dysregulation in adults with ADHD: a systematic review and meta-analysis //Neuroscience & Biobehavioral Reviews. – 2018. -Vol. 84. -p. 359–367
3. 3. Goldman L. S. et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents //Jama. – 1998. – Vol. 279. – №. 14. -p. 1100–1107
4. 4. Pliszka S. et al. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder //Journal of the American Academy of Child & Adolescent Psychiatry. – 2007. – Vol. 46. – №. 7. -p. 894–921
5. 5. Aksoy U. M. What does current Literature tell us for the aetiology of ADHD? //Klinik Psikofarmakoloji Bulteni. – 2018. -Vol. 28. -p. 313–314
6. 6. Sokunbi M. O. Children with ADHD exhibit lower fMRI spectral exponent than their typically developing counterparts. – Organisation for Human Brain Mapping (OHBM), USA., 2018
7. 7. Sen B. et al. A general prediction model for the detection of ADHD and Autism using structural and functional MRI //PloS one. – 2018. -Vol. 13. – №. 4. -p. e0194856
8. 8. Semrud-Clikeman M. et al. Regional volumetric differences based on structural MRI in children with two subtypes of ADHD and controls //Journal of attention disorders. – 2017. -Vol. 21. – №. 12. – p. 1040–1049
9. 9. Wyciszkiewicz A., Pawlak M. A., Krawiec K. Cerebellar Volume in Children with Attention-Deficit Hyperactivity Disorder (ADHD) Replication Study //Journal of child neurology. – 2017. -Vol. 32. – №. 2. -p. 215–221
10. 10. Shaw P. et al. 99. A Large-Scale Study of Cortical and Cerebellar Morphology in ADHD across the Life span: An ENIGMA-ADHD Collaboration //Biological Psychiatry. – 2017. – Т. 81. – №. 10. -p. S41-S42
11. 11. Jagger-Rickels A. C., Kibby M. Y., Constance J. M. Global gray matter morphometry differences between children with reading disability, ADHD, and comorbid reading disability/ADHD //Brain and language. – 2018. – Vol. 185. -p. 54–66
12. 12. Azeredo A., Moreira D., Barbosa F. ADHD, CD, and ODD: Systematic review of genetic and environmental risk factors //Research in developmental disabilities. – 2018. -Vol. 82. -p. 10–19
13. 13. van Lieshout M. et al. The course of neurocognitive functioning and prediction of behavioral outcome of ADHD affected and unaffected siblings //Journal of abnormal child psychology. – 2019. -Vol. 47. – №. 3. -p. 405–419
14. 14. Stein D. S., Harstad E. B., Barbaresi W. J. Attention-Deficit/Hyperactivity Disorder (ADHD) //Care of Adults with Chronic Childhood Conditions. – Springer, Cham, 2016. -p. 39–51
15. 15. dos Santos Nobre J. P. et al. Characterization of Epidemiological ADHD Studies: A Systematic Review //Psychology. – 2017. -Vol. 8. – №. 03. -p. 412
16. 16. Bob P., Konicarova J. Definition, Diagnosis and Epidemiology of Attention Deficit and Hyperactivity Disorder //ADHD, Stress, and Development. – Springer, Cham, 2018. -p. 1–10
17. 17. O’Neill S. et al. Preschool predictors of ADHD symptoms and impairment during childhood and adolescence //Current psychiatry reports. – 2017. -Vol. 19. – №. 12. -p. 95
18. 18. Coghill D. et al. The Age of Onset of Attention-Deficit Hyperactivity Disorder //Age of Onset of Mental Disorders. – Springer, Cham, 2019. -p. 217–236
19. 19. Becker K. et al. Individualized stepwise adaptive treatment for 3–6-year-old preschool children impaired by attention-deficit/hyperactivity disorder (ESCA preschool): study protocol of an adaptive intervention study including two randomised controlled trials within the consortium ESCA life //Trials. – 2020. -Vol. 21. – №. 1. -p. 1–19
20. 20. Wender P. H., Tomb D. A. ADHD: A guide to understanding symptoms, causes, diagnosis, treatment, and changes over time in children, adolescents, and adults. – Oxford University Press, 2016
21. 21. Daly B. P., Nicholls E., Brown R. T. ADHD in Adults. – Hogrefe Publishing, 2016
22. 22. Semeijn E. J. et al. Lifetime stability of ADHD symptoms in older adults //ADHD Attention Deficit and Hyperactivity Disorders. – 2016. -Vol. 8. – №. 1. -p. 13–20
23. 23. Fisher T. et al. ADHD in the aging population: a new differential diagnosis? //Harefuah. – 2019. -Vol. 158. – №. 6. -p. 347
24. 24. Gunes S. Diagnostic confounding: is it absence epilepsy or ADHD? //Dusunen Adam The Journal of Psychiatry and Neurological Sciences. – 2017. -Vol. 30. – №. 4. -p. 391
25. 25. Drechsler R. et al. ADHD: Current Concepts and Treatments in Children and Adolescents //Neuropediatrics. – 2020. – С. Epub ahead of print
26. 26. Ryder J. G., Silva J. M. Mood Disturbance in ADHD Due to a General Medical Condition //Moodiness in ADHD. – Springer, Cham, 2018. -p. 25–38
27. 27. Paucke M. et al. Attention deficit-hyperactivity disorder (ADHD) and comorbid mental disorders: ADHD-specific self-rating scales in differential diagnostics //Der Nervenarzt. – 2018. -Vol. 89. – №. 11. -p. 1287–1293
28. 28. Young J. L., Goodman D. W. Adult attention-deficit/hyperactivity disorder diagnosis, management, and treatment in the DSM-5 era //The primary care companion for CNS disorders. – 2016. -Vol. 18. – №. 6
29. 29. Rigler T. et al. New DSM-5 criteria for ADHD-Does it matter? //Comprehensive psychiatry. – 2016. -Vol. 68. -p. 56–59; Bange F. ADHD: current diagnostic criteria //Médecine thérapeutique/Pédiatrie. – 2016. -Vol. 19. – №. 3. -p. 191–194
30. 30. Tamm L., Epstein J. N., Becker S. P. A preliminary investigation of reaction time variability in relation to social functioning in children evaluated for ADHD //Child neuropsychology. – 2019. -Vol. 25. – №. 7. -p. 885–898
31. 31. Zhao X. et al. Family burden of raising a child with ADHD //Journal of Abnormal Child Psychology. – 2019. -Vol. 47. – №. 8. -p. 1327–1338
32. 32. Wolff S. et al. Accident patterns in trauma surgery patients with and without self-reported ADHD //Journal of neural transmission. – 2019. -Vol. 126. – №. 9. -p. 1163–1173
33. 33. Kittel-Schneider S. et al. Prevalence of ADHD in accident victims: results of the PRADA study //Journal of clinical medicine. – 2019. -Vol. 8. – №. 10. -p. 1643
34. 34. Mogavero F., Jager A., Glennon J. C. Clock genes, ADHD and aggression //Neuroscience & Biobehavioral Reviews. – 2018. -Vol. 91. -p. 51–68
35. 35. Eadeh H. M. et al. Longitudinal evaluation of the role of academic and social impairment and parent-adolescent conflict in the development of depression in adolescents with ADHD //Journal of child and family studies. – 2017. -Vol. 26. – №. 9. -p. 2374–2385
36. 36. Barkley R. A., Fischer M. The Milwaukee Longitudinal Study of Hyperactive (ADHD) Children //Attention Deficit Hyperactivity Disorder: Adult Outcome and Its Predictors. – 2017. -p. 63
37. 37. Bendiksen B. et al. Co-occurrence of ODD and CD in preschool children with symptoms of ADHD //Journal of attention disorders. – 2017. – Vol. 21. – №. 9. -p. 741–752
38. 38. Harvey E. A., Breaux R. P., Lugo-Candelas C. I. Early development of comorbidity between symptoms of attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) //Journal of abnormal psychology. – 2016. -Vol. 125. – №. 2. -p. 154
39. 39. Baweja R., Waxmonsky J. G. Treatment Implications for ADHD Youth with Mood and Anxiety Comorbidity //Current Treatment Options in Psychiatry. – 2018. -Vol. 5. – №. 1. -p. 73–97
40. 40. Sadek J. ADHD and Conduct Disorder (CD) //Clinician’s Guide to ADHD Comorbidities in Children and Adolescents. – Springer, Cham, 2019. – p. 47–59
41. 41. Zuddas A. et al. ADHD treatment //Oxford Textbook of Attention Deficit Hyperactivity Disorder. – 2018. -p. 379
42. 42. Ramsay J. R. The relevance of cognitive distortions in the psychosocial treatment of adult ADHD //Professional Psychology: Research and Practice. – 2017. -Vol. 48. – №. 1. -p. 62
43. 43. Kamimura-Nishimura K. I., Brinkman W. B., Froehlich T. E. Strategies for improving ADHD medication adherence //Current Psychiatry. – 2019. – Vol. 18. – №. 8. -p. 25
44. 44. Feldman M. E., Charach A., Bélanger S. A. ADHD in children and Youth: Part 2-Treatment //Paediatrics & Child Health. – 2018. – Vol. 23. – №. 7. -p. 462–472
45. 45. Hechtman L., Pliszka S. R. New Findings from the Multimodal Treatment of ADHD (MTA) Study Follow-up //66th Annual Meeting. – AACAP, 2019
46. 46. Young C. A. AAP updates ADHD treatment guidelines //Pharmacy Today. – 2019. -Vol. 25. – №. 12. -p. 22
47. 47. Wolraich M. L. et al. ADHD diagnosis and treatment guidelines: a historical perspective //Pediatrics. – 2019. -Vol. 144. – №. 4. -p. e20191682
48. 48. Zappitelli M. Management of ADHD. – 2019
49. 49. Coelho L. F. et al. Group cognitive behavioral therapy for children and adolescents with ADHD //Psicologia: Reflexão e Crítica. – 2017. -Vol. 30
50. 50. Jansen M. NPs' use of guidelines to diagnose and treat childhood ADHD //The Nurse Practitioner. – 2019. -Vol. 44. – №. 7. – p. 37–42
51. 51. Iacobucci G. ADHD: methylphenidate should be first line drug treatment in children, review confirms// British Medical Journal. – 2018.-Vol. 362.-№34.-p.30
52. 52. Arnett A., Stein M. Refining treatment choices for ADHD //The Lancet Psychiatry. – 2018. -Vol. 5. – №. 9. -p. 691–692
53. 53. Mattingly G. W., Wilson J., Rostain A. L. A clinician’s guide to ADHD treatment options //Postgraduate medicine. – 2017. -Vol. 129. – №. 7. -p. 657–666
54. 54. Courtabessis E. et al. Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France //European child & adolescent psychiatry. – 2018. -Vol. 27. – №. 3. -p. 367–376
55. 55. Ornoy A., Spivak A. Cost effectiveness of optimal treatment of ADHD in Israel: a suggestion for national policy //Health economics review. – 2019. -Vol. 9. – №. 1. -p. 24
56. 56. Pelham W. E. et al. The effectiveness of short-and long-acting stimulant medications for adolescents with ADHD in a naturalistic secondary school setting //Journal of attention disorders. – 2017. -Vol. 21. – №. 1. -p. 40–45
57. 57. Vallejo Valdivielso M. et al. Effect of stimulant medications on intelligence quotient scores in a Spanish sample of children and adolescents with ADHD //European Neuropsychopharmacology. -2019. -Vol. 29. -p. S435-S435
58. 58. Cortese S. Debate: are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? //Journal of the American Academy of Child and Adolescent Psychiatry. – 2019. -Vol. 58. – №. 10. -p. 936
59. 59. Stevenson R. D., Wolraich M. L. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder //Pediatric Clinics of North America. – 1989. -Vol. 36. – №. 5. -p. 1183–1197
60. 60. Frankenberger W., Lozar B., Dallas P. The use of stimulant medication to treat Attention Deficit Hyperactive Disorder (ADHD) in elementary school children //Developmental Disabilities Bulletin. – 1990
61. 61. Millichap J. Stimulant Medication for ADHD //Pediatric Neurology Briefs. – 1990. -Vol. 4. – №. 7
62. 62. Clavenna A., Bonati M. Safety and Tolerability of Medications for ADHD //Pharmacovigilance in Psychiatry. – Adis, Cham, 2016. -p. 233–253
63. 63. Kataoka S. H. ADHD among US children and adults: increasing access to care //Psychiatric Services. – 2016. -Vol. 67. – №. 9. -p. 937–937
64. 64. Greydanus D. E., Cates K. W., Sadigh N. Adverse effects of stimulant medications in children and adolescents: focus on drug abuse //International journal of adolescent medicine and health. – 2019. -Vol. 31. – №. 4
65. 65. Kattura R. S., Crismon M. L. Clinically significant interactions with stimulants and other non-stimulants for ADHD //Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. – Adis, Cham, 2016. -p. 535–549
66. 66. Dittmann R. W. et al. Non-stimulants in the treatment of ADHD //Oxford Textbook of Attention Deficit Hyperactivity Disorder. – 2018. -p. 393
67. 67. Markowitz J. S., Yu G. Stimulants and other non-stimulants for attention-deficit/hyperactivity disorder (ADHD) //Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. – Adis, Cham, 2016. -p. 303–327
68. 68. Nageye F., Cortese S. Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD //Expert review of neurotherapeutics. – 2019. -Vol. 19. – №. 7. -p. 707–717
69. 69. Hennissen, L., Bakker, M. J., Banaschewski, T., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Hollis, C. P., Kovshoff, H., McCarthy, S., et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: A systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. // CNS Drugs. -2017.- Vol.31.- №3.- p.199–215
70. 70. Ravishankar V. et al. The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials //Asian Journal of Psychiatry. – 2016. -Vol. 24. -p. 53–58
71. 71. Gayleard J. L., Mychailyszyn M. P. Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology //ADHD Attention Deficit and Hyperactivity Disorders. – 2017. -Vol. 9. – №. 3. -p. 149–160
72. 72. Rezaei G. et al. Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis //Medical journal of the Islamic Republic of Iran. – 2016. -Vol. 30. -p. 325
73. 73. Childress A. C. A critical appraisal of atomoxetine in the management of ADHD //Therapeutics and clinical risk management. – 2016. -Vol. 12. -p. 27
74. 74. Kemper A. R. et al. Attention deficit hyperactivity disorder: Diagnosis and treatment in children and adolescents. – 2018
75. 75. Panther S. G. et al. Off-label prescribing trends for ADHD medications in very young children //The Journal of Pediatric Pharmacology and Therapeutics. – 2017. -Vol. 22. – №. 6. -p. 423–429
76. 76. Singh J. Pharmacotherapeutic options for attention deficit hyperactivity disorder (ADHD) //International Journal of Research in Medical Sciences. – 2017. -Vol. 5. – №. 11. -p. 4677
77. 77. Brinkman W. B., Froehlich T. E., Epstein J. N. Medication for Adolescents with ADHD //ADHD in Adolescents: Development, Assessment, and Treatment. – 2019. -p. 391
78. 78. Rajeh A. et al. Interventions in ADHD: A comparative review of stimulant medications and behavioral therapies //Asian journal of psychiatry. – 2017. -Vol. 25. -p. 131–135
79. 79. Corkum P. et al. The Effects of Extended-Release Stimulant Medication on Sleep in Children with ADHD //Journal of the Canadian Academy of Child and Adolescent Psychiatry. – 2020. -Vol. 29. – №. 1. -p. 33
80. 80. Fosco W. D. et al. Baseline performance moderates stimulant effects on cognition in youth with ADHD //Experimental and clinical psychopharmacology. – 2020.
81. 81. Caye A. et al. Treatment strategies for ADHD: An Evidence-based guide to select optimal treatment //Molecular Psychiatry. – 2019. -Vol. 24. – №. 3. -p. 390–408
82. 82. Greenhill L. L. et al. Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-deficit/hyperactivity disorder //Journal of the American Academy of Child & Adolescent Psychiatry. – 2019
83. 83. Pliszka, S. R. ADHD and Anxiety: Clinical Implications// Journal of Attention Disorders- 2019.-Vol. 23(3) – p. 203–205
84. 84. Yarmolovsky J. et al. Hot executive control and response to a stimulant in a double-blind randomized trial in children with ADHD //European archives of psychiatry and clinical neuroscience. – 2017. -Vol. 267. – №. 1. -p. 73–82
85. 85. Childress A. et al. Single-dose pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate formulation, in healthy adults and in adolescents and children with attention-deficit/hyperactivity disorder //Journal of child and adolescent psychopharmacology. – 2018. -Vol. 28. – №. 1. -p. 10–18
86. 86. Pozzi M. et al. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: A meta-analysis //Journal of affective disorders. – 2018. -Vol. 238. -p. 161–178
87. 87. Waxmonsky J. G., Wilens T. New Research on the Assessment and Management of the Adverse Events with Central Nervous System Stimulants for the Treatment of ADHD in Children //Journal of the American Academy of Child & Adolescent Psychiatry. – 2018. -Vol. 57. – №. 10. -p. S278
88. 88. Faraone S. V. et al. Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder-implications for clinical recognition and intervention //Journal of Child Psychology and Psychiatry. – 2019. -Vol. 60. – №. 2. -p. 133–150
89. 89. Hall C. L. et al. The challenges of implementing ADHD clinical guidelines and research best evidence in routine clinical care settings: Delphi survey and mixed-methods study //BJPsych open. – 2016. -Vol. 2. – №. 1. -p. 25–31
90. 90. Taylor E. ADHD Medication in the Longer Term //Zeitschrift für Kinder-und Jugendpsychiatrie und Psychotherapie. – 2019
91. 91. Inglis S. K. et al. Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: The Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study //BMJ open. – 2016. -Vol. 6. – №. 4
92. 92. Krinzinger H. et al. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence //Neuroscience & Biobehavioral Reviews. – 2019. -Vol. 107. -p. 945–968
93. 93. Gould M. S. et al. Sudden death and use of stimulant medications in youths //American Journal of Psychiatry. – 2009. -Vol. 166. – №. 9. -p. 992–1001
94. 94. Crevier-Quintin E. et al. American Academy of Pediatrics ADHD Clinical Practice Guidelines: Where is the» Neuro» in this Neurobehavioral Disorder? – 2019
95. 95. Hennissen L. et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine //CNS drugs. – 2017. -Vol. 31. – №. 3. -p. 199–215
96. 96. Newcorn J. et al. Methylphenidate vs. Atomoxetine in Youth with ADHD: Comparative Effectiveness and Preference following Treatment with both Medications //Biological Psychiatry. – 2017. -Vol. 81. – №. 10. -p. S346-S347
97. 97. Imagawa H. et al. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine //Neuropsychiatric disease and treatment. – 2018. – Vol. 14. -p. 611
98. 98. Griffiths K. R. et al. Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: the ACTION randomized controlled trial //Journal of psychiatric research. – 2018. -Vol. 102. -p. 57–64
99. 99. Ni H. C. et al. An open-label, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD //Journal of attention disorders. – 2017. -Vol. 21. – №. 1. -p. 27–39
100. 100. Kowalczyk O. S. et al. Methylphenidate and atomoxetine normalize fronto-parietal underactivation during sustained attention in ADHD adolescents //European Neuropsychopharmacology. – 2019. -Vol. 29. – №. 10. -p. 1102–1116
101. 101. Gregoire-Bottex M., Soe K. Adverse Effects of Non-Stimulant ADHD Drugs: Atomoxetine, Alpha-Agonists //Current Psychopharmacology. – 2018. -Vol. 7. – №. 1. -p. 11–14
102. 102. Rubio Morell B., Hernández Expósito S. Differential long-term medication impact on executive function and delay aversion in ADHD //Applied Neuropsychology: Child. – 2019. -Vol. 8. – №. 2. -p. 140–157
103. 103. Kratochvil C. J. et al. A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder //Journal of Child and Adolescent Psychopharmacology. – 2007. -Vol. 17. – №. 2. -p. 175–186
104. 104. Finelli J., Gleason M. M. Psychopharmacologic considerations in early childhood //Clinical Guide to Psychiatric Assessment of Infants and Young Children. – Springer, Cham, 2019. -p. 285–326
105. 105. Reed V. A. et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research //CNS drugs. – 2016. -Vol. 30. – №. 7. -p. 603–628
106. 106. Ryan N., McDougall T. Attention deficit hyperactivity disorder across the lifespan //British Journal of Mental Health Nursing. – 2017. -Vol. 6. – №. 5. -p. 207–210
107. 107. Linden S. et al. Atomoxetine: no increased suicidal risks in children with ADHD //Reactions. – 2016. -Vol. 1601. -p. 6–14
108. 108. Chang Z. et al. Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study //Biological psychiatry. – 2016. -Vol. 80. – №. 12. -p. 916–922
109. 109. Davies M. et al. Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England //European Psychiatry. – 2017. -Vol. 39. -p. 11–16
110. 110. Stevens J. R., Rodgers J. J., Stern T. A. Idiosyncratic Adverse Reactions to Psychotropic Medications //Psychiatric Annals. – 2016. -Vol. 46. – №. 8. -p. 456–465
111. 111. Wolraich M. L. et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents //Pediatrics. – 2019. -Vol. 144. – №. 4. -p. e20192528
112. 112. Alamo C., López-Muñoz F., Sánchez-García J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (ADHD) //Actas Esp Psiquiatr. – 2016. -Vol. 44. – №. 3. -p. 107–12
113. 113. Karako S. et al. Approach to ADHD patients who are unresponsive to standard treatments //Klinik Psikofarmakoloji Bulteni. – 2019. – Т. 29. -p. 440–440
114. 114. Power T. J., Hom J., Huang P. Current Best Practices for Assessing and Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder //Current Treatment Options in Pediatrics. – 2018. -Vol. 4. – №. 1. -p. 94–107
115. 115. Huss M. et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD //European child & adolescent psychiatry. – 2018. -Vol. 27. – №. 10. -p. 1283–1294
116. 116. van Stralen J. P. M. A controlled trial of extended-release guanfacine and psychostimulants on executive function and ADHD //Journal of attention disorders. – 2020. -Vol. 24. – №. 2. – p. 318–325
117. 117. McCracken J. T. et al. Combined stimulant and guanfacine administration in attention-deficit/hyperactivity disorder: a controlled, comparative study //Journal of the American Academy of Child & Adolescent Psychiatry. – 2016. -Vol. 55. – №. 8. -p. 657–666. e1
118. 118. Huss M., Chen W., Ludolph A. G. Guanfacine extended release: a new pharmacological treatment option in Europe //Clinical drug investigation. – 2016. -Vol. 36. – №. 1. -p. 1–25
119. 119. Biederman J. et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder //Pediatrics. – 2008. -Vol. 121. – №. 1. -p. e73-e84
120. 120. Sallee F. R. et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial //Journal of the American Academy of Child & Adolescent Psychiatry. – 2009. -Vol. 48. – №. 2. -p. 155–165
121. 121. Surman C. B. H. et al. Do pharmaceuticals improve driving in individuals with ADHD? A review of the literature and evidence for clinical practice //CNS drugs. – 2017. -Vol. 31. – №. 10. -p. 857–866
122. 122. Schneider G. et al. Weight and height in children and adolescents with attention-deficit/hyperactivity disorder: a longitudinal database study assessing the impact of guanfacine, stimulants, and no pharmacotherapy //Journal of child and adolescent psychopharmacology. – 2019. -Vol. 29. – №. 4. -p. 285–304
123. 123. Corbisiero S. et al. A comparison of cognitive-behavioral therapy and pharmacotherapy vs. pharmacotherapy alone in adults with Attention-Deficit/Hyperactivity Disorder (ADHD)-A randomized controlled trial //Frontiers in Psychiatry. – 2018. -Vol. 9. -p. 571
124. 124. Hyman S., DuPaul G. J., Gormley M. J. Evidence-Based Assessment and Intervention for ADHD in School Psychology //Handbook of Australian School Psychology. – Springer, Cham, 2017. -p. 311–329
125. 125. Bloch M. H. The continuing contributions of multimodal treatment of attention over nearly two decades to initial attention-deficit hyperactivity disorder pharmacotherapy and long-term clinical course //Journal of Child Psychology and Psychiatry, and Allied Disciplines. – 2017. -Vol. 58. – №. 6. – С. 637–639.
126. 126. Wong I. C. K. et al. Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials //The Lancet Psychiatry. – 2019. -Vol. 6. – №. 6. -p. 528–537
127. 127. Safer D. J. Is ADHD really increasing in youth? //Journal of attention disorders. – 2018. -Vol. 22. – №. 2. -p. 107–115
128. 128. Reale L., Bonati M. ADHD prevalence estimates in Italian children and adolescents: a methodological issue //Italian journal of pediatrics. – 2018. -Vol. 44. – №. 1. -p. 108
129. 129. Bergey M. R., Filipe A. M. ADHD in Global Context //Global Perspectives on ADHD: Social Dimensions of Diagnosis and Treatment in Sixteen Countries. – 2018. -p. 1
130. 130. Goodman D. W. et al. Clinical presentation, diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD) in older adults: a review of the evidence and its implications for clinical care //Drugs & aging. – 2016. -Vol. 33. – №. 1. -p. 27–36
131. 131. Moreira-Maia C. R. et al. Are ADHD medications under or over prescribed worldwide? Protocol for a systematic review and meta-analysis //Medicine. – 2018. -Vol. 97. – №. 24
132. 132. Li T. et al. ADHD symptoms in the adult general population are associated with factors linked to ADHD in adult patients //European Neuropsychopharmacology. – 2019. -Vol. 29. – №. 10. -p. 1117–1126
133. 133. Instanes J. T. et al. Adult ADHD and comorbid somatic disease: a systematic literature review //Journal of Attention Disorders. – 2018. -Vol. 22. – №. 3. -p. 203–228
134. 134. Yule A. M. et al. Examining the association between attention deficit hyperactivity disorder and substance use disorders: a familial risk analysis //Journal of psychiatric research. -2017.-Vol. 85.-p. 49–55
135. 135. Martínez-Luna N, Daigre C, Palma-Álvarez F, et al. Psychiatric Comorbidity and Addiction Severity Differences in Patients with ADHD Seeking Treatment for Cannabis or Cocaine Use Disorders// Journal of Attention Disorders. – September 2019. doi:10.1177/1087054719875787
136. 136. Daviss W. B. Depressive disorders and ADHD //Moodiness in ADHD. – Springer, Cham, 2018. -p. 91–109
137. 137. Perugi G. et al. Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD) //Expert opinion on pharmacotherapy. – 2019. -Vol. 20. – №. 12. -p. 1457–1470
138. 138. Fredriksen M., Peleikis D. E. Long-Term Pharmacotherapy of Adults with Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study //Basic & clinical pharmacology & toxicology. – 2016. -Vol. 118. – №. 1. – p. 23–31
139. 139. Alavi Z., Felzer-Kim I. T., Rollins H. H. When stimulants «fail» for children with attention-deficit/hyperactivity disorder //Consultant. – 2020. -Vol. 6. – №. 8. -p. 3–5
140. 140. Chung J. et al. Treatment of attention-deficit/hyperactivity disorder in preschool-age children: Child and adolescent psychiatrists' adherence to clinical practice guidelines //Journal of Child and Adolescent Psychopharmacology. – 2016. -Vol. 26. – №. 4. -p. 335–343
141. 141. Bellato, A., Arora, I., Hollis, C., Groom, M. J. Is autonomic nervous system function atypical in attention deficit hyperactivity disorder (ADHD)? A systematic review of the evidence// Neuroscience & Biobehavioral Reviews. -2020.-Vol.108, -p.182–206
142. 142. Haak C. Diagnosing and Treating ADHD: Clinician Characteristics, Methods of Diagnosis, Diagnostic Rates, and Treatment Recommendations: дис. – Illinois Institute of Technology, 2019
143. 143. Kapalka G. et al. Childhood and Adolescent Disorders: Evidence-Based Integrated Biopsychosocial Treatment of ADHD and Disruptive Disorders //Cognitive Behavioral Psychopharmacology. – 2018. -p. 243
144. 144. Arns M. et al. Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines //Applied Psychophysiology and Biofeedback. – 2020. -Vol. 45. – №. 2. -p. 39–48
145. 145. Radakovic D. M. Stimulant Medication Use in Children and Adolescents Ages 5–17 with Attention Deficit Hyperactivity Disorder (ADHD) to Diminish Intensity of Symptom Impairment and Improve Academic and Social Performance: дис. – Brandman University, 2018
146. 146. Yuki K. et al. How does a real-world child psychiatric clinic diagnose and treat attention deficit hyperactivity disorder? //World journal of psychiatry. – 2016. -Vol. 6. – №. 1. – p. 118
147. 147. Vierhile A. E., Palumbo D., Belden H. Diagnosis and treatment of attention deficit hyperactivity disorder //The Nurse Practitioner. – 2017. -Vol. 42. – №. 10. -p. 48–54